However, the selection of MT1JP as a biomarker in liver cancer is complicated by its apparent dual roles: in addition to being associated with lenvatinib resistance owing to its antiapoptotic ability, some studies have noted that MT1JP is actually a tumor suppressor [193,194]. This evidence concerns the gene MT1JP and neoplasm.